Without controlled body composition measurements, it's hard to interpret anecdotal reports
Medicare Data (2025): Once-weekly GLP-1 RAs (especially semaglutide) showed superior MACE reduction compared to SGLT2 inhibitors in Medicare beneficiaries with atherosclerotic cardiovascular disease (ASCVD)
J Biol Chem 276:29596602 Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, Salmona M, Bonetto V, Mengozzi M, Duffieux F, Miclet E, Bachi A, Vanekerckhove J, Gianazza E, Ghezzi P (2002) Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes
Conversely, no weight loss drug use was associated with an increased risk at five years (RR, 2.96), seven years (RR, 4.02) and 10 years (RR, 4.30) compared with GLP-1 agonist use
It's the gold standard for preserving the integrity of sensitive biological compounds
Whilst some patients report fluctuating appetite suppression or gastrointestinal symptoms during the week, the glucose-lowering efficacy remains consistent
